Thermo Fisher Scientific Inc.

**Strong Financial Performance**: Thermo Fisher reported Q3 2024 revenue of $10.6 billion with adjusted EPS of $5.28, reflecting strong operational performance and a $0.06 EPS increase versus prior guidance. Adjusted operating income was $2.36 billion, and operating margin stood at 22.3%. The company raised its adjusted EPS guidance for the full year to a range of $21.35 to $22.07.

**Sequential Improvement Across Markets**: The company saw sequential improvement in growth across its customer segments, with performance in pharma and biotech declining in the low-single-digits due to a five-point headwind from vaccine and therapy revenue runoff. The academic and government business grew low-single-digits, driven by electron microscopy, while industrial and diagnostic markets remained flat.

**Life Sciences Segment Challenges**: The Life Sciences Solutions segment reported a 4% organic revenue decline year-over-year, primarily impacted by COVID-related revenue runoff. Although there were strong trends in areas like clinical sequencing and bioproduction, the segment struggled with increased competition and market adjustments.